Rahul Kakkar

Rahul is a CEO-Partner at Flagship Pioneering and Chief Executive Officer of Quotient Therapeutics. He is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and working as a practicing physician.

Previously, Rahul served as President and CEO of Tome Biosciences, a biotechnology company developing CRISPR-based large genomic insertion DNA engineering platform technologies. Prior to Tome, Dr. Kakkar was CEO at Pandion Therapeutics, a biologics drug design platform company focused on autoimmune diseases which successfully completed an IPO prior to its acquisition by Merck. Before his role at Pandion, Dr. Kakkar served as founder, Chief Medical Officer and Chief Strategy Officer at Corvidia Therapeutics which was acquired by Novo Nordisk. He was also Director of Emerging Innovations at AstraZeneca. He continues to practice medicine at Brigham and Women’s Hospital and is a lecturer in medicine at Harvard Medical School.

Rahul received his B.A. from Tufts University and his M.D. from the Tufts University School of Medicine.